Campaigns

Treatment of wet AMD campaign

Summary: NICE gives thousands of people hope that their sight might be saved.


Latest news - April 2008

After our two-year campaign, NICE change their decision on the use of sight-saving wet AMD treatments!

For further details about this announcement and key moments in the campaign read campaign news - AMD treatment campaign.

Background

In February 2006 the National Institute for Clinical Excellence (NICE) started appraising two new treatments for wet age-related macular degeneration (AMD). The new treatments (brand names Lucentis and Macugen) are so-called anti-VEGF treatments that are administered through injections in the eye. They stop the bleeding at the back of the eye that causes sight loss in patient with wet AMD.

The appraisal process went through several phases and alarmingly NICE recommended at one point to limit treatment to less than 20 per cent of patients. Persistent lobbying and a huge public outcry that included thousands of people writing to NICE managed to overturn this decision.

Further information

Further information on AMD

For eye health professionals

Back to sight loss campaign homepage

Content author: campaign@rnib.org.uk

Last updated: 02/04/2008 15:32

More info

Quiz

Do blind and partially sighted people watch TV?




Your stories

Jenny's story - Jenny Burgess volunteered for a disability support group run by people with physical disabilities. She was the only staff member with a sight problem. “I depended on a colleague with physical disabilities to give me a lift to work. I have far greater mobility problems than most people with physical disabilities who can drive a car, yet receive less benefit - it’s unfair and unjust.” Join our campaign to make the mobility component of the Disability Living Allowance fair - taken for a ride.